Veraxa Biotech Holding AG (VRXA) Total Non-Current Liabilities (2024 - 2025)
Veraxa Biotech Holding AG (VRXA) posted quarterly Total Non-Current Liabilities of $112.6 million for Q4 2025, up 92.74% year-over-year from $58.4 million in Q4 2024, and up 92.74% quarter-over-quarter from $58.4 million in Q4 2024.
Veraxa Biotech Holding AG (VRXA) Total Non-Current Liabilities (2024 - 2025) Analysis & Trends
Veraxa Biotech Holding AG (VRXA) has reported Total Non-Current Liabilities for 2 consecutive years, with $112.6 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Total Non-Current Liabilities rose 92.74% year-over-year to $112.6 million; the TTM figure through Dec 2025 stood at $112.6 million (up 92.74% YoY), while the FY2025 annual figure was $112.6 million, up 92.74% from the prior year.
- Total Non-Current Liabilities advanced to $112.6 million in Q4 2025 per VRXA's latest filing, from $58.4 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $112.6 million in Q4 2025 and bottomed at $58.4 million in Q4 2024.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 112.57 Mn |
| Dec 31, 2024 | 58.41 Mn |